Business Wire

Suzano sets sales record in 2024 with new mill in Mato Grosso do Sul state and acquisition in the U.S.

Share

Suzano, the world’s largest pulp producer, announces its quarterly results for both the final quarter (4Q24) and the full year (2024). Pulp and paper sales reached a new record of 12.3 million tonnes, rising 7% on 2023, mainly driven by the additional capacity from the new pulp mill in Ribas do Rio Pardo in Mato Grosso do Sul state. Further capacity from the recent acquisition of paperboard mills in the United States has also contributed to the record sales volume.

The higher sales volumes and favorable exchange rates boosting export revenues resulted in net revenues of R$47.4 billion in 2024, 19% higher than in 2023. Adjusted EBITDA grew 31%, to R$23.8 billion, while operational cash generation increased 40%, reaching R$16.2 billion. Suzano reported a net loss of R$6.7 billion due to the accounting impact of US dollar denominated debt and hedging operations translating into Brazilian Real. There is no immediate cash impact of this accounting adjustment and the potential cash effect will only occur at debt and hedging maturity.

Suzano invested R$17.1 billion in 2024, with R$4.5 billion specifically allocated to the new mill - the Cerrado Project - in Ribas do Rio Pardo. The world's largest single pulp production line began operations on July 21 and completed its learning curve process in less than six months, well ahead of expectations and setting a record timeline in the industry's history. The new mill has also contributed to reducing Suzano's pulp cash cost by 6% to R$828/tonne in 2024 versus the prior year.

Beto Abreu, CEO of Suzano, commented:

“We successfully completed our Cerrado Project and made significant strides in our strategy, with the acquisition of assets in the U.S. and a stake in Lenzing, the Austria-based textiles business. Despite these investments, we ended 2024 with lower net leverage than the prior year, reflecting Suzano's discipline in capital allocation, operational competitiveness and financial strength”.

Suzano’s net leverage in U.S. dollars fell from 3.1 times in December 2023 to 2.9 times at the end of 2024, in line with Suzano’s commitment to execute its largest-ever capital investment project within the limits established in the company’s policy. In addition to maintaining robust investment plans, Suzano allocated R$2.8 billion to fund its share buyback program and paying a total of R$1.5 billion as interest on equity to its shareholders.

In the year of its centenary, Suzano reached the mark of 56,000 direct and indirect employees and embarked on an ambitious commitment to invest up to US$100 million over a ten-year period in initiatives focusing on research, knowledge generation and education for sustainability, in collaboration with renowned international institutions, including the University of Cambridge and the non-governmental organization IUCN, among others.

Suzano's central goal is to drive global efforts to protect and restore nature by developing expertise and leadership in sustainability, and accelerating research and education in conservation, climate change, and water resource management.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250212112172/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Visa and Transcard Collaborate to Deliver Advanced Embedded Working Capital Solutions in Freight & Logistics4.11.2025 14:00:00 CET | Press release

New partnership expands the reach of embedded finance for the freight sector, powering operational agility for WebCargo by Freightos ® users Visa and Transcard today announced the launch of a next-generation embedded finance platform, designed to power payments and working capital solutions in the freight and logistics industry. As a part of their joint effort, Visa and Transcard are also collaborating on agentic initiatives for the B2B segment. This alliance puts embedded credit and working capital solutions in the hands of freight forwarders and airline carriers on WebCargo by Freightos (Nasdaq: CRGO), a leading digital booking and payments platform in the freight industry. By combining Visa’s global expertise in commercial solutions with Transcard’s leading-edge payment orchestration technology, WebCargo users can now gain access to flexible credit terms, seamless onboarding and automated reconciliation for air cargo transactions. The solution, built on Visa’s virtual card infrastru

Esri Supports IUCN Global Initiative for Nature-Based Education4.11.2025 14:00:00 CET | Press release

New Collaborative GeoPortal Will Help Deliver Data, Maps, Educational Resources, and ArcGIS Technology for Students, Teachers, and Conservationists Around the World At the 2025 IUCN World Conservation Congress, Esri, the global leader in geographic information system (GIS) technology, announced a joint initiative with the International Union for Conservation of Nature (IUCN) and its Commission on Education and Communication to expand access to data, maps, and GIS technology in support of Nature-based Education (NbE) worldwide. Esri is making a $10 million in-kind donation to enable the development of a new NbE geoportal that will allow students, teachers, and IUCN conservationists around the world to understand and explore our planet through maps and the science of geography, collaborate on critical conservation solutions, and develop critical technical skills for future careers in conservation. This new initiative, now in the pilot phase of consultation and design, will support IUCN’s

Agendia to Present Five Posters Demonstrating the Expanding Clinical Utility of MammaPrint + BluePrint at the 2025 San Antonio Breast Cancer Symposium4.11.2025 13:00:00 CET | Press release

New data from the ongoing FLEX Study highlight the value of real-world evidence in personalizing chemotherapy decisions and improving outcomes in early-stage breast cancer Agendia®, Inc., a leader in precision oncology for breast cancer, today announced it will present new results from the ongoing real-world FLEX Study (NCT03053193) at the 2025 San Antonio Breast Cancer Symposium (SABCS), taking place December 9-12 in San Antonio, Texas. The company will present five posters, led by Agendia investigators and independent academic collaborators, that collectively highlight the broad clinical impact of MammaPrint® + BluePrint® genomic profiling in optimizing treatment decisions and improving outcomes for patients with hormone receptor positive, HER2-negative (HR+/HER2–) early breast cancer (EBC). “We look forward to sharing these new findings from the FLEX Study, which spans more than 20,000 participants across 100 global sites, making it the largest and most diverse real-world evidence c

Nature Communications Study Supports HER2DX as a Genomic Tool for Tailored Therapy in Older Individuals With HER2+ Breast Cancer4.11.2025 13:00:00 CET | Press release

First study to evaluate HER2DX in a randomized trial focused exclusively on older individuals (aged 70–80 years). HER2DX independently predicts long-term survival outcomes in patients treated with trastuzumab with or without chemotherapy. Findings support HER2DX as a tool to guide chemotherapy decisions and de-escalation strategies in older adults. REVEAL GENOMICS, S.L., a Barcelona-based biotechnology company seeking to revolutionize precision oncology through biomarker innovation, today announced the publication of the study “HER2DX in older patients with HER2-positive early breast cancer: extended follow-up from the RESPECT trial of trastuzumab ± chemotherapy” in Nature Communications. This landmark study evaluated the HER2DX genomic assay in 154 individuals aged 70–80 years enrolled in the RESPECT trial (NCT01104935), a randomized phase III study comparing adjuvant trastuzumab with or without chemotherapy. The analysis, known as Trans-RESPECT, is the first to evaluate HER2DX in an

Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months4.11.2025 12:30:00 CET | Press release

Company accelerating commercialization readiness plans by 9-12 months, following completion of COMP006 trial enrollment and positive meeting with FDA on NDA submission strategies for COMP360 in TRD, including potential rolling submissionCompany now plans to disclose 9-week data (Part A) from COMP006 together with 26-week data (Part B) from COMP005 in Q1 2026Disclosure of 26-week (Part B) COMP006 data expected in early Q3 2026Cash position of $185.9 million as of September 30, 2025Conference call on November 4 at 8 am ET (1 pm UK) Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the third quarter 2025 and provided an update on recent progress across its business. “With the completion of COMP006 enrollment and our recent positive discussions with the FDA, we are excited about pulling forward our expected launch timing for COMP360 in TRD by 9-12 mont

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye